News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
GlaxoSmithKline Partner Pronova BioPharma Settles Drug Case with Apotex Inc.; Apotex to Sell Generic Lovaza in U.S. from Q1 2015
March 30, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, March 30 (Reuters) - Norway's Pronova BioPharma (PRON.OL), which supplies the omega-3 heart medicine Lovaza to GlaxoSmithKline (GSK.L), settled a U.S. patent row with generics company Apotex, sending Pronova shares sharply higher.
Twitter
LinkedIn
Facebook
Email
Print
Legal
GlaxoSmithKline
MORE ON THIS TOPIC
Earnings
Pfizer CEO Calls Trump’s Pharma National Security Concerns ‘Legitimate’
April 29, 2025
·
3 min read
·
Annalee Armstrong
Vaccines
HHS Unfreezes Vaxart’s COVID-19 Study, Resumes Funding as Headwinds Batter Vaccines Space
April 29, 2025
·
2 min read
·
Tristan Manalac
FDA
Fact or Fiction? Unpacking FDA Commissioner Marty Makary’s First Interviews
April 25, 2025
·
7 min read
·
Heather McKenzie
Legal
Judge Rules Against Semaglutide Compounders After Shortage Declared Over
April 25, 2025
·
2 min read
·
Tristan Manalac